Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman Sells 6,702 Shares

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 6,702 shares of the business’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $146.03, for a total transaction of $978,693.06. Following the sale, the chief executive officer now directly owns 203,354 shares of the company’s stock, valued at approximately $29,695,784.62. The trade was a 3.19 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Steven Leonard Chapman also recently made the following trade(s):

• On Wednesday, March 5th, Steven Leonard Chapman sold 87,272 shares of Natera stock. The shares were sold at an average price of $143.40, for a total value of $12,514,804.80.
• On Wednesday, January 29th, Steven Leonard Chapman sold 13,685 shares of Natera stock. The stock was sold at an average price of $165.87, for a total value of $2,269,930.95.
• On Wednesday, January 22nd, Steven Leonard Chapman sold 78,553 shares of Natera stock. The shares were sold at an average price of $164.97, for a total value of $12,958,888.41.

Natera Price Performance

Shares of NASDAQ:NTRA opened at $150.87 on Thursday. The company has a 50-day moving average price of $162.25 and a two-hundred day moving average price of $149.27. Natera, Inc. has a twelve month low of $83.13 and a twelve month high of $183.00. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $20.40 billion, a PE ratio of -85.72 and a beta of 1.80.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.01. The business had revenue of $476.10 million during the quarter, compared to analyst estimates of $447.91 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. Equities analysts forecast that Natera, Inc. will post -1.49 EPS for the current year.

Institutional Trading of Natera

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. LRI Investments LLC purchased a new position in Natera during the 4th quarter valued at about $29,000. Blue Trust Inc. boosted its position in shares of Natera by 104.3% in the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 97 shares during the period. Versant Capital Management Inc boosted its position in shares of Natera by 345.8% in the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 166 shares during the period. EverSource Wealth Advisors LLC grew its stake in Natera by 372.9% during the fourth quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company’s stock valued at $52,000 after acquiring an additional 261 shares in the last quarter. Finally, Principal Securities Inc. increased its holdings in Natera by 20.7% during the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock worth $54,000 after acquiring an additional 59 shares during the period. 99.90% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on NTRA. Barclays began coverage on Natera in a research note on Thursday, January 23rd. They set an “overweight” rating and a $200.00 price objective on the stock. BTIG Research restated a “buy” rating on shares of Natera in a report on Friday, February 28th. Sanford C. Bernstein upped their price objective on shares of Natera from $160.00 to $200.00 and gave the stock an “outperform” rating in a research report on Friday, January 10th. Royal Bank of Canada initiated coverage on shares of Natera in a research report on Thursday, March 13th. They set an “outperform” rating and a $251.00 target price on the stock. Finally, The Goldman Sachs Group upped their target price on Natera from $160.00 to $190.00 and gave the company a “buy” rating in a report on Tuesday, January 28th. One research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $178.12.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.